NCT05743868 Metabolic Heterogeneity Underlying Hypertriglyceridemia: Hepatic Triglyceride Biosynthesis in Humans With Different Insulin Resistance Phenotypes
| NCT ID | NCT05743868 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Yale University |
| Condition | Insulin Resistance |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2023-11-16 |
| Primary Completion | 2026-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2023-11-16 with a primary completion date of 2026-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The focus of this cross-sectional study is to determine the effects of tissue-specific (adipose tissue or muscle) vs global (combined) insulin resistance (IR) on hepatic triglyceride biosynthesis in humans, and to determine differential effects of an acute exercise intervention on hepatic triglyceride biosynthesis in these groups.
Eligibility Criteria
Inclusion Criteria: * Ability to give informed consent * Overweight, defined as BMI 25-30 kg/m2 * Modest hypertriglyceridemia, defined as fasting plasma triglycerides 1.5-3.0mM * High risk of insulin resistance, defined as fasting plasma insulin \>64pM * Stable weight for at least 3mo prior to participation Exclusion Criteria: * Active or chronic liver disease, kidney disease, congestive heart failure, unstable angina, history of acute cardiovascular events within 6mo of screening, history of seizures or syncope, or an active infection requiring antimicrobial therapy; * Use of insulin, thiazolidinediones, SGLT2 inhibitors, or sulfonylureas; * Use of fibrates, omega 3 (fish oil), niacin, or PCSK9 antagonists; * Use of systemic glucocorticoids within 60d prior to participation; * Hematocrit \<35%; * Pregnancy of breastfeeding; * Active tobacco use, excessive alcohol intake (\>14U/wk), or history of drug abuse.
Frequently Asked Questions
Who can join the NCT05743868 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Insulin Resistance. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05743868 currently recruiting?
Yes, NCT05743868 is actively recruiting participants. Visit ClinicalTrials.gov or contact Yale University to inquire about joining.
Where is the NCT05743868 trial being conducted?
This trial is being conducted at Amsterdam, Netherlands.
Who is sponsoring the NCT05743868 clinical trial?
NCT05743868 is sponsored by Yale University. The trial plans to enroll 40 participants.